Table 3. Characteristics of patients with adverse events after fiducial placement.
Age/Sex | Tumor | Type | Concurrent ERCP or FNA or CPN | Bile duct stent | No. of fiducials placed | Needle | Antibiotic | Chemotherapy | CyberKnife Radiation | Adverse events | |
1 | 62/M | Pancreatic Ca | Solid | ERCP | FCSEMS | 4 | 19 g | PO Ciprofloxacin | Gemcitabine | Yes | Pain requiring hospitalization |
2 | 65/M | Pancreatic Ca | Solid | ERCP | FCSEMS | 4 | 19 g | IV Ciprofloxacin + PO Augmentin | – | No | Transaminitis, Major bleeding requiring transfusion |
3 | 60/F | CholangioCa | Solid | – | FCSEMS | 2 | 19 g | IV Ciprofloxacin | Gemcitabine, Cisplatin | Yes | Pain |
4 | 79/F | CholangioCa | Solid | – | FCSEMS | 3 | 19 g | – | – | Yes | Pain requiring hospitalization |
5 | 77/F | Ampullary Ca | Solid | – | SEPS | 3 | 19 g | – | – | Yes | Acute Cholangitis |
6 | 69/M | CholangioCa | Solid | – | FCSEMS | 3 | 19 g | IV Ciprofloxacin | Gemcitabine, Cisplatin | Yes | C. difficile colitis, Bacteremia |
7 | 67/M | Pancreatic Ca | Solid | ERCP | FCSEMS | 3 | 19 g | IV Ampicillin + IV Flagyl + PO Augmentin | – | Yes | Pancreatitis |
8 | 63/F | Pancreatic Ca | Solid | ERCP, FNA, CPN | FCSEMS | 3 | 19 g | IV + PO Ciprofloxacin | Gemcitabine | Yes | Pain |
9 | 89/M | IPMN with malignant transformation | Cystic | ERCP, FNA | FCSEMS | 4 | 19 g | IV + PO Ciprofloxacin | – | No | Septic shock |
10 | 71/M | Pancreatic Ca | Solid | – | No stent | 3 | 19 g | IV + PO Ciprofloxacin | Folfirinox | Yes | Minor bleeding |
11 | 83/F | Pancreatic Ca | Mixed | CPN | FCSEMS | 3 | 19 g | IV Ciprofloxacin | Gemcitabine | Yes | Fever, Pain |
12 | 34/F | CholangioCa | Solid | – | UCSEMS | 2 | 19 g | IV Ciprofloxacin | Gemcitabine, Cisplatin | Yes | Fever, Pain requiring hospitalization |
13 | 45/F | Pancreatic NET | Solid | ERCP | UCSEMS | 4 | 19 g | IV + PO Ciprofloxacin | – | Yes | Pancreatitis |
14 | 78/M | Pancreatic Ca | Solid | ERCP | FCSEMS | 3 | 19 g | IV Ciprofloxacin | – | Yes | Pain requiring hospitalization |
15 | 59/F | Pancreatic Ca | Solid | – | No stent | 4 | 22 g | IV Imipenem | – | Yes | Pancreatitis |
16 | 75/F | Pancreatic Ca | Solid | – | FCSEMS | 4 | 22 g | IV + PO Ciprofloxacin | Gemcitabine | Yes | Pain requiring hospitalization |
17 | 68/M | CholangioCa | Solid | – | No stent | 3 | 19 g | IV + PO Ciprofloxacin | Gemcitabine, Cisplatin | Yes | Fever, Pain requiring hospitalization |
18 | 67/M | Pancreatic Ca | Solid | FNA | FCSEMS | 3 | 19 g | IV + PO Ciprofloxacin | – | Yes | Pain, minor bleeding |
19 | 66/M | Pancreatic Ca | Solid | – | No stent | 4 | 19 g | IV Ciprofloxacin | Folfirinox | Yes | Fever requiring hospitalization |
20 | 64/F | Pancreatic Ca | Solid | – | No stent | 4 | 22 g | IV Ciprofloxacin + PO Augmentin | Folfirinox | Yes | Fever |
21 | 73/M | Pancreatic Ca | Solid | – | No stent | 4 | 22 g | IV Ciprofloxacin | – | Yes | Pain |
NET, neuro-endocrine tumor; Ca, carcinoma; IPMN, intraductal papillary mucinous neoplasm; ERCP, endoscopic retrograde cholangiopancreatography; FNA, fine-needle aspiration; CPN, celiac plexus neurolysis; FCSEMS, fully-covered self-expanding metal stent; UCSEMS, uncovered self-expanding metal stent; SEPS, self-expanding plastic stent.